{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:36Z","timestamp":1791388116114,"version":"4.3.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T00:00:00Z","timestamp":1383868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s10067-013-2419-8","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T04:45:04Z","timestamp":1383799504000},"page":"719-723","source":"Crossref","is-referenced-by-count":47,"title":["Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases"],"prefix":"10.1007","volume":"33","author":[{"given":"Ali","family":"Theibich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Locht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,8]]},"reference":[{"key":"2419_CR1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","volume":"325","author":"MK Sharief","year":"1991","unstructured":"Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467\u2013472","journal-title":"N Engl J Med"},{"key":"2419_CR2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","year":"1999","unstructured":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457\u2013465","journal-title":"Neurology"},{"key":"2419_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm0198-078","volume":"4","author":"J Liu","year":"1998","unstructured":"Liu J, Marino MW, Wong G et al (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78\u201383","journal-title":"Nat Med"},{"issue":"6","key":"2419_CR4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10067-005-0097-x","volume":"25","author":"M Tanno","year":"2006","unstructured":"Tanno M, Nakamura I, Kobayshi S et al (2006) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 25(6):929\u2013933","journal-title":"Clin Rheumatol"},{"issue":"4","key":"2419_CR5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","volume":"66","author":"P Lozeron","year":"2009","unstructured":"Lozeron P, Denier C et al (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490\u2013497","journal-title":"Arch Neurol"},{"issue":"6","key":"2419_CR6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/09273948.2010.495814","volume":"18","author":"SY Li","year":"2010","unstructured":"Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18(6):475\u2013481","journal-title":"Ocul Immunol Inflamm"},{"key":"2419_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2007-1019126","volume":"28","author":"A Ascherio","year":"2008","unstructured":"Ascherio A, Munger K (2008) Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28:17\u201328","journal-title":"Semin Neurol"},{"key":"2419_CR8","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00415-010-5591-7","volume":"257","author":"AG Tristano","year":"2010","unstructured":"Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor \u03b1 treatment. J Neurol 257:1421\u20131431","journal-title":"J Neurol"},{"key":"2419_CR9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","volume":"40","author":"MC Fern\u00e1ndez-Espartero","year":"2011","unstructured":"Fern\u00e1ndez-Espartero MC, P\u00e9rez-Zafrilla B, Naranjo A et al (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 40:330\u2013337","journal-title":"Semin Arthritis Rheum"},{"key":"2419_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","volume":"155","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Chen L, Fraunfelder FW et al (2013) Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biological thERapy (SABER) study. Am J Ophthalmol 155:183\u2013189","journal-title":"Am J Ophthalmol"},{"issue":"7412","key":"2419_CR11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","volume":"488","author":"AP Gregory","year":"2012","unstructured":"Gregory AP, Dendrou CA, Attfield KE et al (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488(7412):508\u2013511. doi: 10.1038\/nature11307","journal-title":"Nature"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2419-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-013-2419-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2419-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:57:29Z","timestamp":1559105849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-013-2419-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,8]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2419"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2419-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,8]]}}}